{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T22:05:04Z","timestamp":1788818704471,"version":"build-2803163510"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,6,10]],"date-time":"2019-06-10T00:00:00Z","timestamp":1560124800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,6,10]],"date-time":"2019-06-10T00:00:00Z","timestamp":1560124800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"University of Bergen","award":["Post doc"],"award-info":[{"award-number":["Post doc"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Med Case Reports"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s13256-019-2088-6","type":"journal-article","created":{"date-parts":[[2019,6,10]],"date-time":"2019-06-10T00:02:36Z","timestamp":1560124956000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Enhanced T-lymphocyte infiltration in a desmoid tumor of the thoracic wall in a young woman treated with intratumoral injections of the oncolytic peptide LTX-315: a case report"],"prefix":"10.1186","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3776-6774","authenticated-orcid":false,"given":"Nina Louise","family":"Jebsen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torunn Oveland","family":"Apelseth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans Kristian","family":"Haugland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d8ystein","family":"Rekdal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamina","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bj\u00f8rn Tore","family":"Gjertsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dag Eirik","family":"J\u00f8ssang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,6,10]]},"reference":[{"key":"2088_CR1","volume-title":"WHO classification of tumours of soft tissue and bone","year":"2013","unstructured":"Fletcher CDM, Bridge JA, Hogendoorn PCW, Mertens F, editors. WHO classification of tumours of soft tissue and bone. 4th ed. Lyon: IARC Press; 2013.","edition":"4"},{"issue":"9","key":"2088_CR2","doi-asserted-by":"publisher","first-page":"2817","DOI":"10.1245\/s10434-015-4632-y","volume":"22","author":"DL van Broekhoven","year":"2015","unstructured":"van Broekhoven DL, et al. Time trends in the incidence and treatment of extra-abdominal and abdominal aggressive fibromatosis: a population-based study. Ann Surg Oncol. 2015;22(9):2817\u201323.","journal-title":"Ann Surg Oncol"},{"issue":"12","key":"2088_CR3","doi-asserted-by":"publisher","first-page":"2714","DOI":"10.1038\/emboj.2012.150","volume":"31","author":"T Valenta","year":"2012","unstructured":"Valenta T, Hausmann G, Basler K. The many faces and functions of \u03b2-catenin. EMBO J. 2012;31(12):2714\u201336.","journal-title":"EMBO J"},{"issue":"Suppl 10","key":"2088_CR4","doi-asserted-by":"publisher","first-page":"x158","DOI":"10.1093\/annonc\/mds298","volume":"23","author":"S Bonvalot","year":"2012","unstructured":"Bonvalot S, et al. The treatment of desmoid tumors: a stepwise clinical approach. Ann Oncol. 2012;23(Suppl 10):x158\u201366.","journal-title":"Ann Oncol"},{"issue":"3","key":"2088_CR5","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1093\/annonc\/mdt485","volume":"25","author":"A Gronchi","year":"2014","unstructured":"Gronchi A, et al. Sporadic desmoid-type fibromatosis: a stepwise approach to a non-metastasising neoplasm\u2014a position paper from the Italian and the French Sarcoma Group. Ann Oncol. 2014;25(3):578\u201383.","journal-title":"Ann Oncol"},{"issue":"5","key":"2088_CR6","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.hoc.2013.07.008","volume":"27","author":"S Devata","year":"2013","unstructured":"Devata S, Chugh R. Desmoid tumors: a comprehensive review of the evolving biology, unpredictable behavior, and myriad of management options. Hematol Oncol Clin North Am. 2013;27(5):989\u20131005.","journal-title":"Hematol Oncol Clin North Am"},{"issue":"1","key":"2088_CR7","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1093\/annonc\/mdr051","volume":"23","author":"D Garbay","year":"2012","unstructured":"Garbay D, et al. Chemotherapy in patients with desmoid tumors: a study from the French Sarcoma Group (FSG). Ann Oncol. 2012;23(1):182\u20136.","journal-title":"Ann Oncol"},{"issue":"19","key":"2088_CR8","doi-asserted-by":"publisher","first-page":"4884","DOI":"10.1158\/1078-0432.CCR-10-1177","volume":"16","author":"R Chugh","year":"2010","unstructured":"Chugh R, et al. Efficacy of imatinib in aggressive fibromatosis: results of a phase II multicenter Sarcoma Alliance for Research through Collaboration (SARC) trial. Clin Cancer Res. 2010;16(19):4884\u201391.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"2088_CR9","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1007\/s10637-013-0059-0","volume":"32","author":"JC Jo","year":"2014","unstructured":"Jo JC, et al. A prospective multicenter phase II study of sunitinib in patients with advanced aggressive fibromatosis. Investig New Drugs. 2014;32(2):369\u201376.","journal-title":"Investig New Drugs"},{"issue":"7","key":"2088_CR10","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1016\/j.ejso.2016.02.012","volume":"42","author":"N Eastley","year":"2016","unstructured":"Eastley N, et al. Extra-abdominal desmoid fibromatosis: a review of management, current guidance and unanswered questions. Eur J Surg Oncol. 2016;42(7):1071\u201383.","journal-title":"Eur J Surg Oncol"},{"issue":"13","key":"2088_CR11","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1200\/JCO.2006.10.5015","volume":"25","author":"D Lev","year":"2007","unstructured":"Lev D, et al. Optimizing treatment of desmoid tumors. J Clin Oncol. 2007;25(13):1785\u201391.","journal-title":"J Clin Oncol"},{"issue":"7","key":"2088_CR12","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1080\/028418699432680","volume":"38","author":"JO Fernberg","year":"1999","unstructured":"Fernberg JO, et al. Interferon-induced remission in aggressive fibromatosis of the lower extremity. Acta Oncol. 1999;38(7):971\u20132.","journal-title":"Acta Oncol"},{"issue":"15_suppl","key":"2088_CR13","doi-asserted-by":"publisher","first-page":"e20505","DOI":"10.1200\/jco.2011.29.15_suppl.e20505","volume":"29","author":"J. P. Poulsen","year":"2011","unstructured":"Poulsen JP, Engellau J, Sjeie A, Sloth M, Bjerkehagen B, Zaikova O, Hall S. Scandinavian Sarcoma Group. Human INF-\u03b1 therapy in desmoid tumors: a retrospective study [abstract e20505]. J Clin Oncol. 2011;29(15 Suppl)","journal-title":"Journal of Clinical Oncology"},{"issue":"15","key":"2088_CR14","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1016\/S0024-3205(01)00969-9","volume":"68","author":"G Pagano","year":"2001","unstructured":"Pagano G, et al. The role of oxidative stress in developmental and reproductive toxicity of tamoxifen. Life Sci. 2001;68(15):1735\u201349.","journal-title":"Life Sci"},{"issue":"7","key":"2088_CR15","doi-asserted-by":"publisher","first-page":"2918","DOI":"10.1021\/acs.jmedchem.5b02025","volume":"59","author":"BE Haug","year":"2016","unstructured":"Haug BE, et al. Discovery of a 9-mer cationic peptide (LTX-315) as a potential first in class oncolytic peptide. J Med Chem. 2016;59(7):2918\u201327.","journal-title":"J Med Chem"},{"issue":"21","key":"2088_CR16","doi-asserted-by":"publisher","first-page":"3506","DOI":"10.1080\/15384101.2015.1093710","volume":"14","author":"S Forveille","year":"2015","unstructured":"Forveille S, et al. The oncolytic peptide LTX-315 triggers necrotic cell death. Cell Cycle. 2015;14(21):3506\u201312.","journal-title":"Cell Cycle"},{"issue":"4","key":"2088_CR17","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1097\/PAP.0000000000000077","volume":"22","author":"JA Goldstein","year":"2015","unstructured":"Goldstein JA, Cates JM. Differential diagnostic considerations of desmoid-type fibromatosis. Adv Anat Pathol. 2015;22(4):260\u20136.","journal-title":"Adv Anat Pathol"},{"issue":"33","key":"2088_CR18","doi-asserted-by":"publisher","first-page":"34910","DOI":"10.18632\/oncotarget.5308","volume":"6","author":"LM Eike","year":"2015","unstructured":"Eike LM, et al. The oncolytic peptide LTX-315 induces cell death and DAMP release by mitochondria distortion in human melanoma cells. Oncotarget. 2015;6(33):34910\u201323.","journal-title":"Oncotarget"},{"issue":"8","key":"2088_CR19","doi-asserted-by":"publisher","first-page":"e1338236","DOI":"10.1080\/2162402X.2017.1338236","volume":"6","author":"J Nestvold","year":"2017","unstructured":"Nestvold J, et al. Oncolytic peptide LTX-315 induces an immune-mediated abscopal effect in a rat sarcoma model. Oncoimmunology. 2017;6(8):e1338236.","journal-title":"Oncoimmunology"},{"issue":"4","key":"2088_CR20","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1002\/bjs.10477","volume":"104","author":"ML Janssen","year":"2017","unstructured":"Janssen ML, et al. Meta-analysis of the influence of surgical margin and adjuvant radiotherapy on local recurrence after resection of sporadic desmoid-type fibromatosis. Br J Surg. 2017;104(4):347\u201357.","journal-title":"Br J Surg"},{"issue":"5","key":"2088_CR21","doi-asserted-by":"publisher","first-page":"e154","DOI":"10.1097\/MPH.0000000000000493","volume":"38","author":"NA Dahl","year":"2016","unstructured":"Dahl NA, et al. Gardner fibroma: clinical and histopathologic implications of germline APC mutation association. J Pediatr Hematol Oncol. 2016;38(5):e154\u20137.","journal-title":"J Pediatr Hematol Oncol"},{"issue":"2","key":"2088_CR22","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.ejca.2014.11.005","volume":"51","author":"B Kasper","year":"2015","unstructured":"Kasper B, et al. Management of sporadic desmoid-type fibromatosis: a European consensus approach based on patients\u2019 and professionals\u2019 expertise - a sarcoma patients EuroNet and European Organisation for Research and Treatment of Cancer\/Soft Tissue and Bone Sarcoma Group initiative. Eur J Cancer. 2015;51(2):127\u201336.","journal-title":"Eur J Cancer"},{"issue":"17","key":"2088_CR23","doi-asserted-by":"publisher","first-page":"5034","DOI":"10.1158\/1078-0432.CCR-07-0336","volume":"13","author":"S Signoroni","year":"2007","unstructured":"Signoroni S, et al. Cyclooxygenase-2 and platelet-derived growth factor receptors as potential targets in treating aggressive fibromatosis. Clin Cancer Res. 2007;13(17):5034\u201340.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2088_CR24","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1186\/s12957-016-0944-z","volume":"14","author":"YC Wang","year":"2016","unstructured":"Wang YC, Wong JU. Complete remission of pancreatic head desmoid tumor treated by COX-2 inhibitor-a case report. World J Surg Oncol. 2016;14(1):190.","journal-title":"World J Surg Oncol"}],"container-title":["Journal of Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-019-2088-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13256-019-2088-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-019-2088-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,8]],"date-time":"2020-06-08T23:26:16Z","timestamp":1591658776000},"score":1,"resource":{"primary":{"URL":"https:\/\/jmedicalcasereports.biomedcentral.com\/articles\/10.1186\/s13256-019-2088-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,10]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["2088"],"URL":"https:\/\/doi.org\/10.1186\/s13256-019-2088-6","relation":{},"ISSN":["1752-1947"],"issn-type":[{"value":"1752-1947","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,10]]},"assertion":[{"value":"22 March 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethics approval for the phase I study was obtained from the Regional Committee of Medical Research Ethics, South-Eastern-Norway (no. 2013\/1650) (Rek S\u00f8r \u00d8st D). Written consent was provided by the patient prior to inclusion in the phase I study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"HP and \u00d8R are employees of Lytix Biopharma. All of the other coauthors and the first author declare that they have no competing personal or political interests, commercial associations, or financial interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"177"}}